Currently, the most widely used criteria for assessing response to therapy in high-grade
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Purpose We evaluated the efficacy of bevacizumab, alone and in combination with
irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label …

Background The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to …

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic
glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…

In current clinical practice, histology-based grading of diffuse infiltrative gliomas is the best
predictor of patient survival time. Yet histology provides little insight into the underlying …

Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy,
followed by radiation plus concomitant and adjuvant temozolomide. The treatment of …